Sugentech Inc. develops in-vitro diagnostic systems and products
based on BT-IT-NT convergence technology
Sugentech has announced that it has begun clinical trials of its tuberculosis diagnostic kit in China. Tuberculosis, one of the three major infectious diseases managed by the World Health Organization (WHO), has only been diagnosed using sputum, making accurate and rapid diagnosis difficult. Sugentech has developed the world's first kit for the diagnosis of tuberculosis in blood and has confirmed its excellent clinical performance in the domestic clinical trial earlier this year and has applied for permission to the Korea Food Research Laboratories. The company has been promoting a business alliance with global clinical trials to enter the global diagnostic market of 3 trillion won annually and has recently started clinical trials with one of the three largest TB drug producing countries in the world. Clinical trial results will be available within a few months, and license-out agreements will be concluded with Chinese pharmaceutical companies based on clinical trial results. The company is also negotiating clinical trials and licensing procedures with two Southeast Asian health authorities and is also targeting WHO certification and supply through multinational clinical trials. In fact, the US company Sepheid developed a small molecule diagnostic device using sputum and supplied 660,000 test cases to WHO only in 2018, and sold 6 billion won a year and acquired 5 trillion won in multinational diagnostic company Danaher. A company representative said, "Generally, diagnostic products are in the form of distributor contracts, but the blood-based TB diagnostic kit is worthwhile as an innovative first-in-class product and is negotiating license-out contracts. "We are pursuing a business alliance with a number of global diagnostics companies due to high market demand." Sugentech is a biotechnology company specializing in bio diagnosis. It is based on three diagnostic platforms including multiple immunoblot for general hospitals, on-site diagnosis for small and medium hospital (POCT), and personal personal care. It provides allergy, autoimmune disease, Alzheimer's disease, influenza, tuberculosis, periodontal disease, It is a company that has first-in-class diagnosis technology such as early diagnosis of Alzheimer's disease, blood-based tuberculosis diagnosis, periodontal disease diagnosis, and chronic disease diagnosis.
Sugentech finally completed the acquisition of the K-MAC BioCenter, a subsidary of K-MAC (Korea Materials & Analysis corp). K-MAC BioCenter is specialized in providing high technnology of instrument optimization of in-vitro diagnostics. This is a significant milestone in our long-term strategy to move forward to become a global leading IVD manufacturer.The acquisition of K-MAC BioCenter will be the first major step in that journey and we will take a quantum leap towardsecuring our competitive position in that space. Through the M&A, we will do our best to leverage and expand the two companies’ strength, and will also enhance the R&D and improve our performance.
We, Sugentech Inc., are pleased to inform you that INCLIX Troponin I and HbA1c are CE Certified in July 2017. Based on July 07, 2017, CE Certified products of INCLIX are as follows. INCLIX AnalyzerINCLIX CRPINCLIX PCTINCLIX hsCRPINCLIX dual CRPINCLIX Troponin IINCLIX HbA1c We started selling INCLIX firstly in Europe in 2016 and we are expanding sales area to the Middle East, Asia, Africa etc.We will include new test parameters step by step in 2017 & 2018. For more information or business inquiry, please email to email@example.com Best Regards,Sugentech Inc.
We, Sugentech Inc., are pleased to inform you that INCLIX hs-CRP and Dual – CRP(CRP+ hs-CRP) are CE Certified in April 2017. Based on April 14, 2017, CE Certified products of INCLIX is as follows. INCLIX AnalyzerINCLIX CRPINCLIX PCTINCLIX hs-CRPINCLIX Dual-CRP We started selling INCLIX firstly in Europe in 2016 and we are expanding sales area to the Middle East, Asia, Africa etc. INCLIX Troponin I and HbA1c will be availabel in June and we will include new test parameters step by step in 2017 & 2018. For more information or business inquiry, please email to firstname.lastname@example.org Best Regards,Sugentech Inc.
We, Sugentech Inc., are pleased to inform you that Quantitative Immunoassay POCT Analyzer INCLIX, CRP Test, PCT Test are CE Certified in November 2016. We started selling INCLIX firstly in Europe and we will enlarge sales area to the Middle East, Asia, Africa etc. Including Troponin I and HbA1c, we will include new test parameters step by step in 2017. For more information or business inquiry, please email to email@example.com Best Regards, Sugentech Inc.
We are very glad to inform that Sugentech Inc. was listed in KONEX (KOrea New EXchange, the Korea Stock Market ) on Nov.11, 2016. This is a big day for Sugentech as we officially goes public in the first time. As we commemorate our IPO and welcome new investors into the Sugentech’s family, we believe it is important to express gratitude those who have been with us throughout the journey that’s led us to this day. We will do our best to keep our management in a more transparent, efficient and rational manner. We will increase the corporate value through continuous innovation and sustainable growth, to become a global leader in Point-of-Care testing Diagnostics.